Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Parkinson Disease

ClinicalTrials.gov lists 4,462 trials for Parkinson Disease or a narrower condition beneath it. National Institute of Neurological Disorders and Stroke (NINDS) has the most among industry and government lead sponsors, with 63.

MeSH D010300 Nervous System Diseases C10 Listed by Orphanet as a rare disease
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 385 Phase 1/2 Phase 1/2 102 Phase 2 Phase 2 444 Phase 2/3 Phase 2/3 53 Phase 3 Phase 3 236 Phase 4 Phase 4 172 Not applicable Not applicable 1,974 Observational Observational 1,088 Phase 1 Phase 1 385 Phase 1/2 Phase 1/2 102 Phase 2 Phase 2 444 Phase 2/3 Phase 2/3 53 Phase 3 Phase 3 236 Phase 4 Phase 4 172 Not applicable Not applicable 1,974 Observational Observational 1,088

Trials per phase (log scale)

2 more sections with rows

4,462 of the 4,462 trials are tagged with Parkinson Disease itself; the rest are tagged with a narrower condition beneath it.

Get the Parkinson Disease report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Parkinson Disease trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 10 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Unknown)

Top of scale: 322

1990: 1 trials (Observational 1) 1991: 1 trials (Observational 1) 1992: 3 trials (Observational 2, Phase 2 1) 1993: 3 trials (Observational 1, Not applicable 1, Phase 2 1) 1994: 2 trials (Not applicable 1, Phase 2 1) 1995: 4 trials (Observational 2, Not applicable 1, Phase 3 1) 1996: 1 trials (Phase 2 1) 1997: 6 trials (Observational 4, Phase 3 1, Phase 2 1) 1998: 10 trials (Observational 3, Not applicable 2, Phase 4 1, Phase 3 3, Phase 2 1) 1999: 8 trials (Observational 1, Phase 3 3, Phase 2/3 1, Phase 2 3) 2000: 17 trials (Observational 5, Phase 3 3, Phase 2 6, Phase 1 3) 2001: 16 trials (Observational 6, Phase 3 5, Phase 2 2, Phase 1 3) 2002: 30 trials (Observational 6, Not applicable 5, Phase 4 3, Phase 3 6, Phase 2/3 2, Phase 2 7, Phase 1/2 1) 2003: 42 trials (Observational 11, Not applicable 2, Phase 4 3, Phase 3 8, Phase 2/3 1, Phase 2 12, Phase 1/2 1, Phase 1 4) 2004: 58 trials (Observational 13, Not applicable 7, Phase 4 3, Phase 3 15, Phase 2 16, Phase 1/2 1, Phase 1 3) 2005: 54 trials (Observational 9, Not applicable 8, Phase 4 5, Phase 3 10, Phase 2 12, Phase 1/2 2, Phase 1 8) 2006: 93 trials (Observational 27, Not applicable 10, Phase 4 12, Phase 3 13, Phase 2/3 2, Phase 2 19, Phase 1/2 2, Phase 1 8) 2007: 95 trials (Observational 15, Not applicable 16, Phase 4 14, Phase 3 21, Phase 2/3 3, Phase 2 20, Phase 1/2 1, Phase 1 5) 2008: 74 trials (Observational 19, Not applicable 13, Phase 4 7, Phase 3 6, Phase 2/3 4, Phase 2 12, Phase 1/2 4, Phase 1 9) 2009: 128 trials (Observational 29, Not applicable 22, Phase 4 13, Phase 3 19, Phase 2/3 3, Phase 2 14, Phase 1/2 8, Phase 1 20) 2010: 109 trials (Observational 30, Not applicable 27, Phase 4 6, Phase 3 15, Phase 2/3 1, Phase 2 18, Phase 1/2 2, Phase 1 10) 2011: 122 trials (Observational 34, Not applicable 28, Phase 4 12, Phase 3 10, Phase 2/3 3, Phase 2 16, Phase 1/2 5, Phase 1 14) 2012: 126 trials (Observational 35, Not applicable 37, Phase 4 11, Phase 3 7, Phase 2/3 3, Phase 2 17, Phase 1/2 4, Phase 1 12) 2013: 154 trials (Observational 50, Not applicable 60, Phase 4 6, Phase 3 8, Phase 2/3 2, Phase 2 11, Phase 1/2 2, Phase 1 15) 2014: 167 trials (Observational 34, Not applicable 80, Phase 4 8, Phase 3 10, Phase 2 9, Phase 1/2 1, Phase 1 25) 2015: 191 trials (Observational 43, Not applicable 94, Phase 4 2, Phase 3 10, Phase 2/3 3, Phase 2 19, Phase 1/2 4, Phase 1 16) 2016: 187 trials (Observational 32, Not applicable 95, Phase 4 11, Phase 3 5, Phase 2/3 1, Phase 2 29, Phase 1/2 1, Phase 1 13) 2017: 201 trials (Observational 51, Not applicable 91, Phase 4 9, Phase 3 5, Phase 2/3 2, Phase 2 20, Phase 1/2 6, Phase 1 17) 2018: 224 trials (Observational 49, Not applicable 106, Phase 4 4, Phase 3 8, Phase 2/3 2, Phase 2 24, Phase 1/2 9, Phase 1 22) 2019: 282 trials (Observational 70, Not applicable 143, Phase 4 8, Phase 3 10, Phase 2/3 1, Phase 2 18, Phase 1/2 4, Phase 1 28) 2020: 239 trials (Observational 56, Not applicable 125, Phase 4 3, Phase 3 9, Phase 2/3 1, Phase 2 19, Phase 1/2 4, Phase 1 22) 2021: 322 trials (Other 1, Observational 85, Not applicable 178, Phase 4 7, Phase 3 5, Phase 2/3 4, Phase 2 23, Phase 1/2 2, Phase 1 17) 2022: 282 trials (Observational 76, Not applicable 150, Phase 4 5, Phase 3 3, Phase 2/3 3, Phase 2 17, Phase 1/2 7, Phase 1 21) 2023: 297 trials (Observational 82, Not applicable 163, Phase 4 7, Phase 3 1, Phase 2/3 3, Phase 2 16, Phase 1/2 6, Phase 1 19) 2024: 290 trials (Observational 67, Not applicable 174, Phase 4 2, Phase 3 3, Phase 2/3 3, Phase 2 15, Phase 1/2 5, Phase 1 21) 2025: 309 trials (Observational 78, Not applicable 168, Phase 4 3, Phase 3 6, Phase 2/3 3, Phase 2 18, Phase 1/2 10, Phase 1 23)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 288
2025 309
2024 290
2023 297
2022 282
2021 322
2020 239
2019 282
2018 224
2017 201

Showing 10 of 37 earlier years.

Start your 14-day trial Email me all 37 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 340 trials starting in 2026 and about 320 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 451 trials still running at the 2026-10-09 snapshot; registered median of 20 months across 2,572 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Parkinson Disease trials in? (10)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 385
Phase 1/2 102
Phase 2 444
Phase 2/3 53
Phase 3 236
Phase 4 172
Not applicable 1,974
Observational 1,088
Expanded access 7
Unknown 1

How many Parkinson Disease trials are recruiting? (12)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 205
Recruiting 616
Enrolling by invitation 76
Active, not recruiting 148
Available 1

Showing 5 of 12 statuses.

Start your 14-day trial Email me all 12 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Parkinson Disease trials? (6)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Institute of Neurological Disorders and Stroke (NINDS) 63
Bial - Portela C S.A. 56
Boehringer Ingelheim 42
VA Office of Research and Development 42
AbbVie 30

Showing 5 of 6 sponsors.

Start your 14-day trial Email me all 6 sponsors as a PDF

Which drugs are being tested for Parkinson Disease? (7)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Levodopa 49
BIA 9-1067 40
KW-6500 31
Istradefylline 19
Safinamide 17

Showing 5 of 7 drugs.

Start your 14-day trial Email me all 7 drugs as a PDF

Interventions as named in the registry (8)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Group R Rasagiline 48
Rotigotine TTS (Test) 39
Pramipexole ER 35
Exercise 34
Control (placebo) group 23

Showing 5 of 8 interventions.

Start your 14-day trial Email me all 8 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Parkinson Disease trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Parkinson's disease 236 36
Fall 225 65
Pneumonia 220 75
Syncope 134 49
Osteoarthritis 131 35

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Parkinson Disease? (4,425)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
[<sup>18</sup>F]MFBG PET/CT imaging of myocardial sympathetic innervation in healthy controls and patients with parkinson's disease: dosimetry and pharmacokinetics. European journal of nuclear medicine and molecular imaging 2026 Yes
The role of lifestyle interventions in symptom management and disease modification in Parkinson's disease. The Lancet. Neurology 2026 Yes
Mid-long term efficacy of dihydroergotoxine mesylate in treatment of sialorrhea in Parkinson's disease. Clinical neurology and neurosurgery 2026 Yes
Global, regional and national burden of Parkinson's disease, 1990-2021: Update from the GBD 2021 study. Journal of the neurological sciences 2026 Yes
Temporal Dynamics and Cross-Sectional and Longitudinal Factors Associated With Motor Reserve and Outcome in Patients With Parkinson Disease. Neurology 2026 Yes

Showing 5 of 4,425 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.

Browse all condition evidence pages